Table 16, Celecoxib in patients with bleeding ulcer history - Analgesics for Osteoarthritis

Warning: The NCBI web site requires JavaScript to function. more...

Study Sample Size	Treatments	Recurrent Ulcer Bleeding (Difference, 95% CI)	Other Adverse Events	Withdrawals due to Adverse Events
Chan 2002²³³ n=287	Celecoxib 200 mg bid Diclofenac 75 mg bid plus omeprazole 20 mg qd	4.9% vs. 6.3% at 6 months (−1.5%, −6.8 to 3.8; NS)	No differences	13% vs. 12%, NS^*
Lai 2005²³⁴^† n=242	Celecoxib 200 mg qd Naproxen 250 mg tid plus lansoprazole 30 mg qd	3.7% vs. 6.3% at 6 months (−2.6; −9.1 to 3.7; NS)	No differences for all but dyspepsia: 15% vs. 5.7%, p=0.02	10% vs. 7.4%, NS
Chan 2007²³⁵ n=273	Celecoxib 200 mg bid plus esomeprazole 20mg bid Celecoxib 200 mg bid	0% vs. 19% at median 13 months (p=0.03)	No differences	5.8% vs. 7.4%, NS

: bid = twice daily; CI = confidence interval; NS = not significant; qd = three times daily; tid = twice daily
*: Includes withdrawals due to lack of efficacy
†: Open trial

Analgesics for Osteoarthritis: An Update of the 2006 Comparative Effectiveness Review [Internet].

Comparative Effectiveness Reviews, No. 38.

Chou R, McDonagh MS, Nakamoto E, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.